Immutep Balance Sheet Health
Financial Health criteria checks 6/6
Immutep has a total shareholder equity of A$115.6M and total debt of A$897.9K, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are A$123.8M and A$8.1M respectively.
Key information
0.8%
Debt to equity ratio
AU$897.92k
Debt
Interest coverage ratio | n/a |
Cash | AU$103.73m |
Equity | AU$115.64m |
Total liabilities | AU$8.15m |
Total assets | AU$123.79m |
Recent financial health updates
No updates
Recent updates
Immutep: Realizing The Expected Catalysts, With More To Come
May 01Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
Oct 04Immutep secures €1.8M cash in French government's research tax credit
Sep 23Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Aug 30Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761
Jul 06Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Jun 12Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
Mar 21Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%
Jun 21Immutep reveals anti-LAG-3 research program
Jun 08Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination
May 26Immutep completes recruitment in efti mid-stage study in head & neck cancer
Jan 07Immutep secures U.S. patent for Eftilagimod Alpha
Dec 29Immutep +72% after breast cancer trial shows promising survival data
Dec 09Immutep to enroll additional patients in mid-stage study with its lead cancer program
Nov 19Immutep rallies on Australian patent grant for IMP701 antibody
Nov 09Financial Position Analysis
Short Term Liabilities: IMMP's short term assets (A$113.0M) exceed its short term liabilities (A$6.6M).
Long Term Liabilities: IMMP's short term assets (A$113.0M) exceed its long term liabilities (A$1.6M).
Debt to Equity History and Analysis
Debt Level: IMMP has more cash than its total debt.
Reducing Debt: IMMP's debt to equity ratio has reduced from 21.3% to 0.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMMP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMMP has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 27.1% each year.